Literature DB >> 31283925

MicroRNA-92b-3p suppresses angiotensin II-induced cardiomyocyte hypertrophy via targeting HAND2.

Xue-Ju Yu1, Yu-Qing Huang2, Zhi-Xin Shan2, Jie-Ning Zhu2, Zhi-Qin Hu3, Lei Huang4, Ying-Qing Feng5, Qing-Shan Geng6.   

Abstract

AIMS: The pathological cardiac hypertrophy will develop into heart failure, which has no effective treatment currently. Previous studies have proved that microRNAs (miRNAs) participate in the development of cardiac hypertrophy and regulate the pathological progress. In this study, we want to investigate the role of microRNA-92b-3p (miR-92b-3p) in cardiomyocyte hypertrophy and the mechanisms involved.
MATERIALS AND METHODS: Neonatal mouse ventricular cells (NMVCs) were isolated from the hearts of 1-3-d-old newborn C57BL6 mice. The isolated NMVCs were induced hypertrophic phenotype by Angiotensin-II (Ang-II) and the cell size was examined by FITC-phalloidin staining assay. The expression of miR-92b-3p was determined by quantitative real-time PCR (qRT-qPCR). MRNA and protein level of β-MHC, ACTA1 and HAND2 in NMVCs transfected with miR-92b-3p mimic and inhibition were assessed by RT-qPCR assay and western blot assay, respectively. Dual luciferase assay was used to verify the interaction between miR-92b-3p and the 3'-untranslated region (UTR) of HAND2 gene. KEY
FINDINGS: MiR-92b-3p and HAND2 were significantly increased in Ang-II-induced NMVCs. Overexpression of miR-92b-3p can ameliorate Ang-II-induced cardiomyocyte hypertrophy. MiR-92b-3p negatively regulated HAND2 expression at the transcriptional level. Both miR-92b-3p mimic and HAND2 siRNA could efficiently inhibit Ang-II-induced hypertrophy in mouse cardiomyocytes. SIGNIFICANCE: MiR-92b-3p inhibits Ang-II-induced cardiomyocyte hypertrophy via targeting HAND2.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Cardiomyocyte; HAND2; MicroRNA-92b-3p

Mesh:

Substances:

Year:  2019        PMID: 31283925     DOI: 10.1016/j.lfs.2019.116635

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Omega-3 fatty acid protects cardiomyocytes against hypoxia-induced injury through targeting MiR-210-3p/CASP8AP2 axis.

Authors:  Xueju Yu; Fengyao Liu; Yuting Liu; Bingqing Bai; Han Yin; Haochen Wang; Yingqing Feng; Huan Ma; Qingshan Geng
Journal:  Mol Cell Biochem       Date:  2021-03-31       Impact factor: 3.396

2.  TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cells.

Authors:  Pengcheng Huang; Yao Hu; Yuping Duan
Journal:  J Mol Histol       Date:  2022-01-27       Impact factor: 2.611

Review 3.  Gene therapy for cardiovascular diseases in China: basic research.

Authors:  Jiali Deng; Mengying Guo; Guoping Li; Junjie Xiao
Journal:  Gene Ther       Date:  2020-04-27       Impact factor: 5.250

4.  Expression of miRNAs in plasma exosomes derived from patients with atrial fibrillation.

Authors:  Zhang Wei; Zhang Bing; Qian Shaohuan; Wang Yanran; Sun Shuo; Tang Bi; Zhu Feiyu; Zhang Heng; Gao Qin; Kang Pinfang
Journal:  Clin Cardiol       Date:  2020-09-17       Impact factor: 2.882

Review 5.  microRNAs Mediated Regulation of the Ribosomal Proteins and its Consequences on the Global Translation of Proteins.

Authors:  Abu Musa Md Talimur Reza; Yu-Guo Yuan
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

6.  MiR-410-3p facilitates Angiotensin II-induced cardiac hypertrophy by targeting Smad7.

Authors:  Guizhi Jia; Chunguang Liang; Wenhui Li; Hongliang Dai
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

7.  The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.

Authors:  Simonetta Andrea Licandro; Luca Crippa; Roberta Pomarico; Raffaella Perego; Gianluca Fossati; Flavio Leoni; Christian Steinkühler
Journal:  Skelet Muscle       Date:  2021-07-22       Impact factor: 4.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.